Objective: Fat Aussie mice (foz/foz) are morbidly obese, glucose intolerant and have liver steatosis that develops into steatohepatitis on a high-fat diet. The cannabinoid 1 receptor (CB1) antagonist SR141716 has been shown to improve obesityassociated metabolic complications in humans and rodent models. The aim of this study was to assess the effect of SR141716 in foz/foz mice. Design: Male wildtype (WT) and foz/foz mice were fed a chow or high-fat diet (45% saturated fat). Vehicle or SR141716 (10 mg kg À1 per day) was administered in jelly once daily for 4 weeks from 4 months of age. Results: Foz/foz mice were obese but had less epididymal adipose tissue mass than fat-fed WT mice despite being significantly heavier. Liver weight was increased by twofold in foz/foz compared with WT mice and showed significant steatogenesis associated with impaired liver function. Foz/foz and fat-fed WT mice were glucose intolerant as determined by oral glucose tolerance test. In chow-fed foz/foz mice, SR141716 reduced body weight, liver weight, reversed hepatosteatosis and glucose intolerance. Subcutaneous white adipose tissue gene expression of the macrophage-specific marker Cd68 reflected the improvements in the metabolic status by SR141716 in these mice.
Introduction
Obesity is a disease of increasing global prevalence characterized by excess storage of fat and chronic inflammation. 1 The obese state preconditions individuals to the metabolic syndrome, increasing the risk for the development of Type 2 diabetes and cardiovascular disease. 2 Insulin resistance is the main underlying characteristic of the metabolic syndrome and there is mounting evidence that storage of fat in nonadipose tissues, such as liver and muscle, contribute to reduced insulin action. 3, 4 The endocannabinoid system is a silent physiological system that is transiently activated under normal circumstances but may be overactivated in obesity. [5] [6] [7] Endocannabinoids are long chain fatty-acid derivatives and comprise part of an endogenous neuroendocrine signaling system. They exert both central and peripheral metabolic effects that are widespread but poorly understood. 8 Cannabinoid receptor type 1 (CB1) is expressed in the cerebral cortex, basal ganglia and cerebellum in the brain and in skeletal muscle, liver, bone, gastrointestinal tract, pancreatic beta-cells and white adipose tissue (WAT). 9 Animal studies implicate a key role for CB1 in peripheral lipid partitioning and insulin action.
SR141716 (trade names: Rimonabant, Acomplia) is a selective CB1 inverse agonist, which significantly improves metabolic risk factors associated with obesity and Type 2 diabetes. 10 Clinical trials have shown that SR141716 treatment for 1 year reduces body weight, serum triglyceride and fasting insulin in overweight patients. 11 Elucidation of the effects of SR141716 have been extended in diet-induced obese mice and Zucker rats to show further beneficial effects on hepatic steatosis and insulin resistance. [12] [13] [14] [15] Blockage of CB1 receptors in the central nervous system results in reduced food intake and this may contribute to its beneficial effect on body weight. 16 However, there is also evidence that it has central nervous system-independent effects directly on adipose tissue to reduce cellular proliferation 17 and stimulate adiponectin production. 18 Foz/foz mice have an 11-bp deletion in the Alms1 gene. 19 The exact function of the ALMS1 protein is unknown, but immunohistochemistry shows that it is localized to primary cilium, suggestive of a role in intracellular transport. 20 The phenotype of the foz/foz mouse closely resembles that of the metabolic syndrome in humans. These mice are morbidly obese, hyperphagic, glucose intolerant and exhibit liver steatosis that develops into steatohepatitis when on a highfat diet. 21, 22 Fasting plasma glucose levels increase progressively with age, insulin levels are increased 20-fold compared with wild-type littermates, total cholesterol is elevated and adiponectin levels are significantly reduced. On a high-fat diet, cholesterol levels are further increased and adiponectin levels are reduced to a quarter of the level in wild-type (WT) mice. 21 In this study, we treated foz/foz mice with the CB1 blocker, SR141716 to enhance understanding of mechanisms regulating metabolic disorders such as fatty liver and insulin resistance. We found that SR141716 was very effective in reversing metabolic defects in foz/foz mice and this was associated with changes in gene expression of a macrophagespecific marker in WAT.
Materials and methods

Ethics statement
All experimental procedures performed in this study were approved by the University of Sydney Animal Ethics Committee (L02/8-2007/3/4620).
Animals and diets
Male foz/foz and WT mice on NOD/B10 background were bred at the Australian National University Medical School (Canberra) and transported to the University of Sydney at 4 weeks of age. Mice were maintained in a specific pathogen-free environment under a 12 h light-dark cycle at all times. Mice were placed on either a standard chow diet (5.4% fat by weight; energy content 12 MJ kg
À1
, Specialty Feeds, Glen Forrest, Western Australia) or a high-fat diet (23% fat by weight; 20 MJ kg À1 ; SF03-020 Specialty Feeds) at 4 weeks of age for 16 weeks. After 12 weeks on diets, the mice were randomly assigned to one of the two treatment groups (n ¼ 6-8 in each end group). The intervention group (SR141716, SanofiAventis, Macquarie Park, New South Wales, Australia) was treated daily for 4 weeks with SR141716 (10 mg kg À1 per day PO solubilised in 0.1% tween-80 and set into jelly cubes (0.5 ml) sweetened with 5% sucrose). The control group was given plain sweetened jelly (0.5 ml) daily for 4 weeks. Each mouse received a 1-week run-in with plain jelly before the commencement of treatment. Body weight was measured weekly for the duration of the experiment. Food intake was measured before and during the treatment phase of the study. ). Liver, subcutaneous and epididymal WAT were removed and weighed. Samples of liver were fixed in formalin for histological studies.
Plasma measurements
Blood samples were taken for the measurements of plasma lipids and liver biochemistry (automated assay, Pathology Department, The Canberra Hospital, Australia). Plasma leptin and adiponectin levels were analyzed by commercial ELISA (LINCO Research, St Charles, MO, USA). Nonesterified fatty acids were determined using an acyl-CoA oxidase-based colorimetric kit (WAKO NEFA-C, WAKO Pure Chemical Industries, Osaka, Japan).
Gene expression
Total RNA was extracted from mice subcutaneous fat using RNeasy Lipid Tissue Mini kit (Qiagen, Victoria, Australia). RNA was reverse transcribed using a SuperScriptVilo cDNA Reverse Transcriptase kit (Invitrogen, Victoria, Australia). Real-time PCR was carried out on a StepOnePlus system (Applied Biosystems, Victoria, Australia) using SYBR Green-based detection. Oligonucleotide primer sequences (Sigma-Genosys, Castle Hill, Australia) of the mouse genes studied were the following:
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Statistical analysis
All experimental data were arranged into eight groups: chow-fed WT mice with or without SR141716, fat-fed WT mice with or without SR141716, chow-fed foz/foz mice with or without SR141716 and fat-fed foz/foz mice with or without SR141716. Analysis of group data was based on three a priori contrasts designed to study the principal questions of the study: WT vs foz/foz (effect of genotype), chow-fed vs fat-fed (effect of diet) and vehicle vs SR141716 (effect of drug).
Groups were compared using analysis of variance with Fisher's protected least-square difference test. Statistical calculations were performed using a commercial software package, Statview TM (Abacus Concepts, Berkeley, CA, USA).
Results are reported as means±s.e. Po0.05 was considered statistically significant.
Results
Foz/foz mutation increases body weight and food intake Mice with the mutation in the Alms 1 gene (foz/foz) were significantly heavier than WT littermates when fed either the standard chow or high-fat diet ( Figure 1 ). High-fat feeding increased body weight in both WT and foz/foz mice compared with mice on a chow diet. Foz/foz mice were hyperphagic compared with WT mice consuming significantly more energy per day irrespective of diet (Po0.01) ( Table 1) . Daily oral treatment with SR141716 did not change food intake within any of the groups; however, it did result in reduced body weight in both chow and high-fatfed foz/foz mice. SR141716 had no effect on body weight of WT mice on any diet.
Foz/foz mice display impaired capacity to store fat in adipose tissue Placing WT mice on a high-fat diet for 16 weeks increased the amount of both epididymal and subcutaneous WAT by twofold as expressed as a percentage of body weight (Po0.0001, Table 1 ). Foz/foz mice on a chow diet had more adipose tissue than WT mice but less than high-fat-fed WT mice despite their significantly increased body weight. Fat feeding foz/foz mice did not increase the percentage of epididymal or subcutaneous adipose tissue, indicating an impaired capacity to expand these adipose depots. A 4 weeks treatment with SR141716 significantly reduced subcutaneous adipose tissue in both WT and foz/foz chow-fed mice (Po0.05). However, SR141716 increased epididymal fat stores in chow-fed foz/foz mice. SR141716 had no effect on adiposity in WT or foz/foz mice fed a high-fat diet.
SR141716 ameliorates hepatosteatosis and steatohepatitis in foz/foz mice Feeding WT mice a high-fat diet had no effect on the weight of liver as a percentage of body weight (Figure 2a) . Accordingly, SR141716 treatment did not alter liver weights in WT mice. However, livers of foz/foz mice fed a chow diet were twofold larger than their WT littermates. Feeding these mice a high-fat diet exacerbated this difference with liver weights being threefold heavier than WT mice on either diet. SR141716 treatment normalized the liver weight in the chow-fed foz/foz mice, resulting in similar sized livers to WT mice (Po0.0001 for all differences). However, SR141716 had no effect on size of the liver of fat-fed foz/foz mice.
In keeping with this data, serum liver enzymes measured as an indication of liver function followed a similar pattern (Figures 2b and c) . Fat feeding had no significant effect on liver function in WT mice. Serum alanine transaminase (ALT) levels were significantly raised in chow-fed foz/foz, suggesting hepatocyte damage (Po0.001, Figure 2c ). SR141716 treatment reduced ALT levels in chow-fed foz/foz mice to levels comparable with chow-fed WT mice (Po0.05) and tended to reduce aspartate transaminase levels (not significant). Fat feeding in foz/foz mice significantly elevated levels of ALT and aspartate transaminase compared with fatfed WT mice (Po0.001 for both), and SR141716 significantly lowered aspartate transaminase and ALT levels, though they remained above normal levels. Serum ALT levels positively correlated with total cholesterol levels ( Figure 7c , r 2 ¼ 0.613,
Po0.0001).
Liver pathology was demonstrated in histological studies of the liver (Figure 3 ). WT mice, fed a high-fat diet for 16 weeks developed steatosis compared with chow-fed WT mice. The ALMS1 mutation resulted in development of steatosis even in those mice fed a standard chow diet. This progressed to steatohepatitis when the mice were fed high fat. Treatment with SR141716 reversed steatosis in both the WT and foz/foz mice were fed either chow (solid line) or high-fat diet (dashed line) and treated with SR141716 (10 mg kg À1 per day; dotted line) or vehicle orally from 12 weeks. Significant differences between final body weights are shown in Table 1 .
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Effects of
fat-fed WT and chow-fed foz/foz mice, and ameliorated steatohepatitis in the fat-fed foz/foz mice.
SR141716 improves plasma lipid profile in fat-fed mice
There was no difference in serum lipid levels between WT and foz/foz mice on a chow diet (Table 1) . Feeding both groups a high-fat diet resulted in significantly elevated serum cholesterol concentrations, though the difference was exaggerated in the foz/foz mice. SR141716 treatment reduced cholesterol in both WT and foz/foz mice fed high fat. Serum triglyceride concentrations were significantly elevated by high-fat feeding only in the foz/foz mice, and SR141716 returned levels to normal. There was no significant difference in serum nonesterified fatty acid between any of the groups.
Glucose intolerance and markers of insulin sensitivity are improved in chow-fed foz/foz mice Fasting plasma insulin levels were significantly elevated in foz/foz mice. Treatment with SR141716 reduced insulin in 
Po0.0001).
Chow-fed foz/foz mice also had significantly impaired glucose tolerance with a markedly elevated blood glucose response to an oral glucose load for the duration of the test compared with WT chow-fed mice (Figure 5a ). This was not further exacerbated by high-fat feeding (Figures 5b and c) . Treatment with SR141716 for 4 weeks resulted in an improvement in glucose tolerance in chow foz/foz mice, but was unable to normalize it entirely (Po0.05). SR141716 also reduced post-challenge blood glucose levels in fat-fed foz/foz mice, however, these did not reach statistical significance.
Adipose tissue mRNA expression of the macrophage-specific marker Cd68 antigen is ameliorated by SR141716 To assess macrophage infiltration into subcutaneous WAT in these mice, we measured Cd68 antigen mRNA levels, a specific macrophage marker. 23 Cd68 mRNA expression in WT mice was not affected by high-fat feeding or SR141716. Foz/foz mice had increased levels of Cd68 in adipose tissue compared with WT mice and high-fat feeding exacerbated this. Unlike in WT mice, SR141716 treatment did significantly reduce Cd68 expression in foz/foz mice on both diets ( Figure 6 ). Cd68 adipose tissue expression was strongly correlated with both liver weight and serum liver enzymes (Figures 7d and e, r 2 ¼ 0.67 and r 2 ¼ 0.577, respectively, Po0.0001 for both). Cd68 mRNA also negatively correlated with adiponectin levels but the relationship was weaker (Figure 7b , r 2 ¼ À0.375, Po0.0005). Effects of SR141716 in fat Aussie mice KS Bell-Anderson et al
Discussion
In this study we investigated the effects of SR141716 in WT and obese foz/foz (ALMS1 mutant) mice fed a chow and highfat diet. SR141716 had minimal effects in chow-fed WT mice, improved cholesterolemia and ameliorated hepatosteatosis in fat-fed WT mice. SR141716 exerted the greatest effect in chow-fed foz/foz mice, improving glucose tolerance and other markers of insulin sensitivity, reversing hepatomegaly and steatosis, improving liver function and ameliorating adipose tissue macrophage infiltration. Similar effects were observed in fat-fed foz/foz mice treated with SR141716 with respect to liver function, weight, steatohepatitis, dyslipidemia and macrophage marker expression in adipose, but little change in insulin sensitivity parameters. Foz/foz mice fed a high-fat diet were heavier but not 'fatter' per se than chow-fed foz/foz or WT mice, as the size of the epididymal adipose tissue depot was smaller when expressed as a percentage of body weight. Fat-fed WT controls had twice as much epididymal adipose than fat-fed foz/foz mice despite the ALMS1 mutant mice being heavier. These data are consistent with the hypothesis that foz/foz mice have a problem storing adipose tissue appropriately, and instead store lipid in non-adipose tissues such as the liver. 22 Measurement of percentage fat mass by dual-emission X-ray absorptiometry, or magnetic resonance imaging could provide more accurate information on the relative adiposity of the foz/foz mice and determine the extent of ectopic deposition of lipid. Histological studies confirm that fat is sequestered and stored in the liver in these mice and is associated with increased liver weight and elevated liver enzyme levels. SR141716 essentially reversed this effect but only in chow foz/foz mice. CB1 receptor antagonism directly on hepatocytes may account for the improvements we see in foz/foz mice. Liver-specific CB1 receptor knockout mice are protected against hepatic steatosis, insulin resistance and dyslipidemia 24 associated with reduced lipogenic pathways in the liver. Activation of the CB1 receptor in mice has the complementary effect, increasing the expression of the lipogenic transcription factor SREBP-1c and its downstream targets, similarly in isolated hepatocytes CB1 agonism increases fatty acid synthesis. 25 Foz/foz mice on a chow diet have increased expression of liver genes favoring lipid storage, which fail to upregulate when the mice are given a high-fat diet leading to an exacerbation of lipid accumulation in the liver. 21 There is evidence from our data that CB1 receptor antagonism does alleviate this lipid accumulation in the liver and improve liver function, contributing to enhanced insulin sensitivity, most notably in chow-fed foz/foz mice. The liver pathology in fat-fed foz/foz mice is significantly advanced (Figure 3 ) and may reduce the efficacy of CB1 antagonism in hepatocytes explaining why steatohepatitis, and other metabolic parameters, are ameliorated by SR141716 but not reversed completely to the same extent as in the chow-fed foz/foz mice. Resistance of liver to the actions of adiponectin, leptin and insulin has been reported in these mice previously and may be due to a similar mechanism. 21 Foz/foz mice, on a chow diet, treated with SR141716, increased their epididymal fat pad mass consistent with re-diversion of lipid away from the liver and into adipose tissue, but this was not evident in high-fat-fed foz/foz mice providing another explanation for why insulin sensitivity could not be improved in these mice with SR141716. It is unclear how the ALMS1 mutation directly affects hepatocytes, and there remains the possibility that endocannabinoid signaling in these mice is disrupted but is restored by SR141716. SR141716 in this study was given to mice orally in a jelly suspension but at a similar dose to that reported by others. Daily gavage of the drug was desirable, given the control that could have been achieved for precise dosing, but the local ethics committee did not approve this. Consequently, it is not known exactly how much of the drug was consumed daily and whether there was a difference in consumption between groups. It is possible that the WT mice ate less of the drug than foz/foz mice, given the foz/foz's voracious appetite and may explain why we did not observe similar effects of SR141716 in WT mice, especially in fat-fed WT mice, compared with other diet-induced models of obesity. 13, 15 Even if the dose was substantially lower in fat-fed WT mice, the drug did have an effect on improving liver steatosis.
There is emerging evidence implicating important peripheral effects of SR141716, independent of its anorectic action, in the treatment of obesity and metabolic disease. 15, 25 . Dietinduced obese mice, treated with SR141716, show a greater reduction in body weight than pair-fed mice, indicating an additional action of the drug, independent of food intake. 13, 15 Our data support a role for peripheral effects of Effects of SR141716 in fat Aussie mice KS Bell-Anderson et al cannabinoid blocker 1 antagonism, as we observed improvements in the metabolic profile in fat-fed WT and foz/foz mice with SR141716 treatment, that were not associated with significant change in food intake and body weight.
SR141716 has been shown previously to abolish hepatic steatosis in obese Zucker fa/fa rats associated with improvements in hepatomegaly, liver enzymes and adiponectin. 26 In our study, adiponectin levels were significantly reduced in foz/foz mice and improved by SR141716 treatment but only in chow-fed mice. This is consistent with previous findings by Bensaid et al. 27 in which adiponectin expression in adipose tissue and cultured adipocytes is increased in the presence of SR141716. It is not likely in our study that an increase in adiponectin could account for all of the improvements in the metabolic profile, as circulating adiponectin levels were low and unchanged in fat-fed foz/foz mice given the drug. Adiponectin exerts beneficial insulin-sensitising and anti-inflammatory actions, and may therefore, in part, have contributed to the improvements in insulin action in chow-fed foz/foz mice. Migrenne et al.
28
investigated the effects of SR141716 in adiponectin-deficient mice on a high-fat diet, and demonstrated that SR141716 was unable to improve insulin sensitivity in these mice compared with WT; however, the adiponectin knockout mice reduced body weight in response to the drug similarly to WTs. The expression of Cd68 antigen, measured here as a marker of macrophage-specific infiltration into subcutaneous WAT, and thus an indicator of adipose tissuerelated inflammation, was significantly ameliorated by SR141716 in foz/foz mice, irrespective of diet. Sugamura et al. 29 have observed anti-inflammatory effects of SR141716 on macrophages in culture and noted increased expression of CB1 receptor in macrophages undergoing monocytemacrophage differentiation. As the CB1 receptor is so widely expressed, and appears to have metabolic consequences Effects of SR141716 in fat Aussie mice KS Bell-Anderson et al directly in a number of tissues, it is difficult to delineate the effects. However, the extent to which SR141716 exerts its effects within individual tissues could be further investigated with histological studies of the adipose tissue, including measurement of adipocyte size, number, morphology and macrophage infiltration as indications of adipose tissue function. Recently, Jourdan et al. 30 have reported improvements in adipose tissue metabolism in response to SR141716 and suggest that this may have a key factor in improving liver steatosis in high-sucrose high-fat-fed mice.
In conclusion, this study highlights the effects of SR141716, or other CB1 receptor antagonists in improving metabolic parameters in obesity peripherally. SR141716 coordinately improved dyslipidemia, hepatic steatosis and liver function, insulin action and adipose tissue inflammation in chow-fed obese mice with an ALMS1 mutation. SR141716 was less effective in fat-fed foz/foz mice, the reasons for which are unclear and require additional investigation. The data implicates the endocannabinoid system in the mediation of whole-body metabolism and further research is needed to clearly elucidate the actions of endocannabinoids in peripheral tissues.
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